2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107010
    Esprolol 396654-09-4 98%
    Esprolol is an orally active and potent β-adrenergic receptor antagonist. Esprolol is rapidly metabolized by blood and tissue esterases to form the active metabolite amoxolol. Esprolol holds potential for research in exercise-induced angina.
    Esprolol
  • HY-107037
    Tolmesoxide 38452-29-8 98%
    Tolmesoxide (RX71107) is a peripheral vascular dilator with blood pressure lowering activity. Tolmesoxide has shown direct vasodilation in the human forearm arterial bed and dorsal hand vein. Tolmesoxide can dose-dependently increase blood flow in the forearm and produce dilation during contraction of the dorsal hand veins. Tolmesoxide can be used to study high blood pressure and angina.
    Tolmesoxide
  • HY-107054
    ESP-31015 413624-55-2 98%
    ESP-31015 (ETC-1001) is an orally active and non-fibrate based PPARα agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research.
    ESP-31015
  • HY-107080
    RPR-109891 169512-56-5 98%
    RPR-109891 is an orally active glycoprotein IIb/IIIa peptide antagonist. RPR-109891 can decrease platelet count and reduce platelet survival time. RPR-109891 can be used for the research of cardiovascular disease, such as myocardial infarction.
    RPR-109891
  • HY-107155
    β-Blocker B-24/76 104970-08-3 98%
    β-Blocker B-24/76 is a beta adrenoceptor blocker. β-Blocker B-24/76 exhibits beta 1-adrenoceptor blocking and beta 2-adrenoceptor stimulating properties. β-Blocker B-24/76 can suppress the increased ornithine decarboxylase activity in hypertrophied hearts. β-Blocker B-24/76 can be used for the research of cardiovascular disease.
    β-Blocker B-24/76
  • HY-10722A
    DX-9065a free base 150612-55-8 98%
    DX-9065a free base is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a free base has low activity against other serine proteases. DX-9065a free base has strong anticoagulant actions.
    DX-9065a free base
  • HY-107461
    LY2623091 1162264-07-4 98%
    LY2623091 is a mineralocorticoid receptor antagonist for the treatment of refractory hypertension. LY2623091 exhibits CYP3A4-dependent clearance and synergistic effects with CYP3A4 inhibitors.
    LY2623091
  • HY-107530
    3F8 159109-11-2 98%
    3F8 is a potent and selective GSK-3β inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases.
    3F8
  • HY-107567
    Carcinine 56897-53-1 98%
    Carcinine (β-Alanylhistamine) is a selective and orally active histamine H3 receptor antagonist with a Ki of 0.2939 μM. Carcinine can reduce histamine content. Carcinine exhibits anti-oxidant activity and neuroprotective effects. Carcinine shows positive inotropic effect and can reduce blood sugar and blood lipid levels. Carcinine can be used for the researches of inflammation, neurological, cardiovascular and metabolic disease, such as retinal damage, seizure and diabetes.
    Carcinine
  • HY-107590
    GR144053 trihydrochloride 1215333-48-4 98%
    GR 144053 trihydrochloride is a selective and non-peptic GPIIb/IIIa inhibitor (IC50=37 nM).
    GR144053 trihydrochloride
  • HY-107630
    RU 26752 76676-33-0 98%
    RU 26752 is a steroid hormone receptor antagonist. RU 26752 can prevent hypertension caused by aldosterone (HY-113313) in rats.
    RU 26752
  • HY-107644
    AQ-RA 741 123548-16-3 98%
    AQ-RA 741 is a potent and selective M 2 antagonist. AQ-RA 741 inhibits the vagally or agonist-induced bradycardia in rats, cats and guinea-pigs. AQ-RA 741 is used in bradycardiac disorders research.
    AQ-RA 741
  • HY-107762
    CGS35066 261619-50-5 98%
    CGS35066 is a potent and selective aminophosphonate inhibitor of endothelin-converting enzyme-1 (ECE-1). CGS 35066 inhibits the activity of human ECE-1 and rat kidney neutral endopeptidase 24.11 (NEP) in vitro with IC50 values of 22 nM and 2.3 μM, respectively.
    CGS35066
  • HY-107901
    Pparδ agonist 1 1902161-12-9 98%
    Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
    Pparδ agonist 1
  • HY-107918
    Alkaloids, Rauwolfia 8063-17-0 98%
    Alkaloids, Rauwolfia is an extract of the whole root of Rauwolfia serpentina with antihypertensive effect.
    Alkaloids, Rauwolfia
  • HY-107966
    Heparin calcium (MW 15000-19000) 37270-89-6 98%
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 15000-19000)
  • HY-108040
    NCX-6560 803728-45-2 98%
    NCX-6560 is an orally active nitric oxide releasing derivative of atorvastatin that inhibits cholesterol biosynthesis and has anti-inflammatory and antithrombotic activity.
    NCX-6560
  • HY-108055
    Urantide 669089-53-6 98%
    Urantide is a selective and competitive urotensin-II (UT) receptor antagonist peptide (pKB=8.3) that blocks human urotensin-II (hU-II)-induced contractions in rat thoracic aorta ex vivo. Urantide can be used to study the (patho)physiological role of hU-II in the mammalian cardiovascular system.
    Urantide
  • HY-108120
    L-162537 167027-99-8 98%
    L-162537 is a competitive human angiotensin II receptor 1 (AT1) and receptor 2 (AT2) antagonist with an IC50=1.7 nM for AT1. L-162537 inhibits Ang II-mediated vasoconstriction, blood pressure elevation and related pathological signaling pathways. L-162537 is promising for research of angiotensin II-related cardiovascular diseases such as hypertension.
    L-162537
  • HY-108136
    Bisindolylmaleimide X 131848-97-0 98%
    Bisindolylmaleimide X (Ro 31-8425, BIM-X) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X can be used for research on the immune system and cardiovascular diseases.
    Bisindolylmaleimide X
Cat. No. Product Name / Synonyms Application Reactivity